Angelini Industries, the multi-sector Italian industrial group operating in 21 countries with 5,800 employees, has launched Angelini Ventures, a global corporate venture capital initiative, with a €300 million capital commitment. Angelini Ventures will build and invest in early-stage companies that develop innovative ideas and solutions in biotechnologies, digital health and life sciences.

Angelini Ventures will invest across Europe, North America, and Israel with a focus on brain health and consumer segments such as women, children and the elderly. The company is headquartered in Rome with a global team located in multiple innovation hubs. Angelini Ventures has already made global investments of €60 million. The current investment portfolio includes Argobio, a Paris-based biotech venture studio; Angelini Lumira Biosciences Fund, a North American fund that invests in early-stage companies; and Pretzel Therapeutics, a Boston-based leading mitochondrial therapeutics company.

“We have put a lot of work into the development of Angelini Ventures, whose mission will be to invest at international level in high-potential ideas, opportunities and projects that use technology to transform the future of the global health system. Thanks to our specific skills and expertise, our ambition is to not only further develop our business but also, and above all, to give voice and life to solutions that have a positive impact on patients and communities", said Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Industries.

“Through Angelini Ventures, entrepreneurs will partner with experts and healthcare leaders who deeply understand the challenges of the healthcare industry and the evolving needs of patients and consumers”, added Paolo Di Giorgio, Chief Executive Officer of Angelini Ventures.